These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21172105)

  • 41. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance.
    Porten SP; Whitson JM; Cowan JE; Cooperberg MR; Shinohara K; Perez N; Greene KL; Meng MV; Carroll PR
    J Clin Oncol; 2011 Jul; 29(20):2795-800. PubMed ID: 21632511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer.
    Pruthi RS; Johnstone I; Tu IP; Stamey TA
    Urology; 1997 May; 49(5):737-42. PubMed ID: 9145980
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostate cancer volume at biopsy predicts clinically significant upgrading.
    Dong F; Jones JS; Stephenson AJ; Magi-Galluzzi C; Reuther AM; Klein EA
    J Urol; 2008 Mar; 179(3):896-900; discussion 900. PubMed ID: 18207180
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors predicting prostatic biopsy Gleason sum under grading.
    Stackhouse DA; Sun L; Schroeck FR; Jayachandran J; Caire AA; Acholo CO; Robertson CN; Albala DM; Polascik TJ; Donatucci CF; Maloney KE; Moul JW
    J Urol; 2009 Jul; 182(1):118-22; discussion 123-4. PubMed ID: 19447436
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease.
    Reese AC; Cooperberg MR; Carroll PR
    J Urol; 2010 Jul; 184(1):114-9. PubMed ID: 20478578
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
    Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
    BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment.
    Soloway MS; Soloway CT; Eldefrawy A; Acosta K; Kava B; Manoharan M
    Eur Urol; 2010 Dec; 58(6):831-5. PubMed ID: 20800964
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease.
    Klotz LH
    Can J Urol; 2005 Feb; 12 Suppl 1():53-7; discussion 101-2. PubMed ID: 15780167
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence.
    Sim HG; Telesca D; Culp SH; Ellis WJ; Lange PH; True LD; Lin DW
    J Urol; 2008 May; 179(5):1775-9. PubMed ID: 18343432
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pathological features after radical prostatectomy in potential candidates for active monitoring.
    Griffin CR; Yu X; Loeb S; Desireddi VN; Han M; Graif T; Catalona WJ
    J Urol; 2007 Sep; 178(3 Pt 1):860-3; discussion 863. PubMed ID: 17631347
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer.
    Whitson JM; Porten SP; Hilton JF; Cowan JE; Perez N; Cooperberg MR; Greene KL; Meng MV; Simko JP; Shinohara K; Carroll PR
    J Urol; 2011 May; 185(5):1656-60. PubMed ID: 21419438
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.
    Tosoian JJ; Trock BJ; Landis P; Feng Z; Epstein JI; Partin AW; Walsh PC; Carter HB
    J Clin Oncol; 2011 Jun; 29(16):2185-90. PubMed ID: 21464416
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Active surveillance as a treatment option for prostate cancer.
    Hegarty J; Bailey DE
    Semin Oncol Nurs; 2011 Nov; 27(4):260-6. PubMed ID: 22018405
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The feasibility of expectant management with inner-city men with newly diagnosed localized prostate cancer.
    Anai S; Nakamura K; Chang MN; Pendleton J; Yacoub S; Rosser CJ
    J Health Care Poor Underserved; 2008 Feb; 19(1):164-70. PubMed ID: 18263992
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A stochastic approach to risk management for prostate cancer patients on active surveillance.
    Prisman EZ; Gafni A; Finelli A
    J Theor Biol; 2011 Sep; 284(1):61-70. PubMed ID: 21723300
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Active surveillance for prostate cancer].
    Dariane C
    Prog Urol; 2015 Nov; 25(14):884-7. PubMed ID: 26184043
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer.
    Boevee SJ; Venderbos LD; Tammela TL; Nelen V; Ciatto S; Kwiatkowski M; Páez A; Malavaud B; Hugosson J; Roobol MJ
    Eur J Cancer; 2010 Nov; 46(17):3082-9. PubMed ID: 21047590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.